Fig. 5
From: Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
Multivariate Cox proportional hazards regression analysis of composite disease progression among cancer patients with COVID-19 receiving azvudine and Paxlovid.
